https://scholars.lib.ntu.edu.tw/handle/123456789/592746
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Lin, Donna S-H | en_US |
dc.contributor.author | TZUNG-DAU WANG | en_US |
dc.contributor.author | Buranakitjaroen, Peera | en_US |
dc.contributor.author | Chen, Chen-Huan | en_US |
dc.contributor.author | Cheng, Hao-Min | en_US |
dc.contributor.author | Chia, Yook Chin | en_US |
dc.contributor.author | Sukonthasarn, Apichard | en_US |
dc.contributor.author | Tay, Jam Chin | en_US |
dc.contributor.author | Teo, Boon Wee | en_US |
dc.contributor.author | Turana, Yuda | en_US |
dc.contributor.author | Wang, Ji-Guang | en_US |
dc.contributor.author | Kario, Kazuomi | en_US |
dc.date.accessioned | 2022-01-21T02:49:50Z | - |
dc.date.available | 2022-01-21T02:49:50Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/592746 | - |
dc.description.abstract | Hypertension is a worldwide epidemic that continues to grow, with a subset of patients responding poorly to current treatment available. This is especially relevant in Asia, which constitutes 61% of the global population. Hypertension in Asia is a unique entity that is often salt-sensitive, nocturnal, and systolic predominant. Sacubitril/valsartan is a first-in-class angiotensin receptor neprilysin inhibitor that was first used in heart failure with reduced ejection fraction. Sacubitril inhibits neprilysin, a metallopeptidase that degrades natriuretic peptides (NPs). NPs exert sympatholytic, diuretic, natriuretic, vasodilatory, and insulin-sensitizing effects mostly via cyclic guanosine monophosphate (cGMP)-mediated pathways. As an antihypertensive agent, sacubitril/valsartan has outperformed angiotensin II receptor type 1 blockers (ARBs), with additional reductions of office systolic blood pressures ranging between 5 and 7 mmHg, in multiple studies in Asia and around the globe. The drug was well tolerated even in the elderly or those with chronic kidney disease. Its mechanisms of actions are particularly attractive for treatment of hypertension in Asia. Sacubitril/valsartan offers a novel, dual class, single-molecule property that may be considered as first-line antihypertensive therapy. Further investigations are needed to validate its safety for long-term use and to explore other potentials such as in the management of insulin resistance and obesity, which often coexist with hypertension in Asia. | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY | en_US |
dc.relation.ispartof | Journal of clinical hypertension (Greenwich, Conn.) | en_US |
dc.subject | Asian patients; angiotensin receptor neprilysin inhibitor; antihypertensive therapy | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | sacubitril plus valsartan; aminobutyric acid derivative; angiotensin receptor; angiotensin receptor antagonist; antihypertensive agent; dipeptidyl carboxypeptidase inhibitor; membrane metalloendopeptidase; tetrazole derivative; Asia; blood pressure regulation; clinical feature; drug mechanism; drug safety; evidence based medicine; human; hypertension; insulin resistance; long term care; obesity; prevalence; Review; aged; drug combination; epidemiology; heart failure; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Asia; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Receptors, Angiotensin; Tetrazoles | - |
dc.title | Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe | en_US |
dc.type | journal article | en |
dc.type | review | en_US |
dc.identifier.doi | 10.1111/jch.14120 | - |
dc.identifier.pmid | 33305531 | - |
dc.identifier.scopus | 2-s2.0-85097424703 | - |
dc.identifier.isi | WOS:000597298000001 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85097424703 | - |
dc.relation.pages | 556 | en_US |
dc.relation.journalvolume | 23 | en_US |
dc.relation.journalissue | 3 | en_US |
dc.relation.pageend | 567 | en_US |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.openairetype | review | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Cardiovascular Center | - |
crisitem.author.orcid | 0000-0002-7180-3607 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。